Researchers have determined that dominant B cell receptor (BCR) clones in peripheral blood may predict the onset of clinical signs and symptoms of RA…
Effects of Obesity on Sustained Remission in Early RA
A new study examined the independent effects of excess weight and obesity on achieving sustained remission in rheumatoid arthritis (RA) patients. Researchers found that within three years of RA diagnosis, overweight and obese patients were significantly less likely to achieve sustained remission than patients with healthy body mass indices (BMIs). Higher BMIs were also associated with persistent disease activity…
Upadacitinib Promising for RA Patients
Upadacitinib proved safe and effective in RA patients who had inadequate responses to conventional disease-modifying anti-rheumatic drugs…
RISE Continues to Improve Offerings for Providers
ACR members are realizing what they have at their fingertips—a registry fully staffed with knowledgeable people ready to help them succeed under MIPS. This valuable resource allows members to do what they do best: Treat patients with rheumatoid arthritis (RA), which is one of the primary goals of the Rheumatology Informatics System for Effectiveness (RISE)…
Pain Links Fibromyalgia & RA
Many patients with rheumatoid arthritis (RA) report pain despite excellent control of inflammation with immunotherapies. Variable degrees of coexisting fibromyalgia (FM) may explain this disparity. RA patients who have the highest 2011 ACR FM survey criteria scores appear to share neurobiologic features consistently observed in FM patients. This study is the first to provide neuroimaging evidence that RA is a mixed pain state, with many patients’ symptoms being related to the central nervous system rather than to classic inflammatory mechanisms…
FDA Approves Baricitinib for RA Patients
The FDA has approved baricitinib in a 2 mg tablet dose to treat patients with moderate to severe active rheumatoid arthritis…
Disease-Modifying Antirheumatic Drugs Cut RA Risk
NEW YORK (Reuters Health)—Disease-modifying antirheumatic drugs (DMARDs) reduce the risk of developing rheumatoid arthritis (RA) in patients with early undifferentiated arthritis, researchers from France report. Several studies have suggested that conventional or biological DMARDs might interfere with the pathogenic process and prevent more established forms of RA, but it remains unclear whether these drugs are…
Targeted Rheumatoid Arthritis Treatment Does Not Improve Mental Health
NEW YORK (Reuters Health)—Effective pharmacotherapy of rheumatoid arthritis (RA) is not associated with meaningful improvements in mental health, according to a systematic review and meta-analysis. “We were surprised by the small effect sizes for mental-health outcomes across all of the treatments included in this review, but particularly for the anti-TNF versus disease-modifying antirheumatic drug (DMARD)…
AbbVie’s RA Drug Succeeds in Late Stage Study
(Reuters)—Abbvie Inc. says its experimental drug met the main goal of halting progression of moderate to severe rheumatoid arthritis (RA) in a late-stage trial. The drug, upadacitinib, was tested as a monotherapy in patients who have not been treated with chemotherapy agent methotrexate. Upadacitinib, which belongs to a class of drugs known as JAK inhibitors,…
Research Shows High Adherence to Performance Measures for RA Cohort
New research examines the adherence rates for system-level performance measures in Canada. Using data from the Canadian Early Arthritis Cohort that spanned eight years, researchers determined the percentage of RA patients seen in yearly follow-up with the number of gaps between visits, the percentage of RA patients treated with a disease-modifying anti-rheumatic drug and number days from diagnosis to the initiation of treatment. The results: High adherence to system-level performance measures was found in this early RA cohort, with small declines in performance with the increasing length overtime…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 30
- Next Page »